A Phase IIB Test-of-Concept, Randomized, Double-Blind, Placebo-Controlled, International Clinical Trial to Evaluate the Efficacy, Safety, and Immunogenicity of a Multiclade HIV-1 DNA Plasmid Vaccine, VRC-HIVDNA016-00-VP, Followed by a Multiclade Recombinant Adenoviral Vector Vaccine, VRC-HIVADV014-00-VP, in HIV Uninfected Persons.

Trial Profile

A Phase IIB Test-of-Concept, Randomized, Double-Blind, Placebo-Controlled, International Clinical Trial to Evaluate the Efficacy, Safety, and Immunogenicity of a Multiclade HIV-1 DNA Plasmid Vaccine, VRC-HIVDNA016-00-VP, Followed by a Multiclade Recombinant Adenoviral Vector Vaccine, VRC-HIVADV014-00-VP, in HIV Uninfected Persons.

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 03 Dec 2015

At a glance

  • Drugs VRC-HIVADV014-00-VP (Primary) ; VRC-HIVDNA016-00-VP (Primary)
  • Indications HIV-1 infections
  • Focus Pharmacodynamics; Registrational; Therapeutic Use
  • Acronyms PAVE 100
  • Most Recent Events

    • 17 Jul 2008 Status changed from initiated to withdrawn prior to recruitment, according to an Eurekalert media release.
    • 27 Dec 2007 Initiation of this trial has been delayed from the third quarter of 2007 to at least the second quarter of 2008.
    • 07 Aug 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top